메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urg…

- Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 -- At an AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts gathered to address platinum resistance in advanced ovarian cancer with Antibody Drug Conjugates (ADCs). The discussion underscored the pressing need to rethink traditional definitions of platinum resistance and explore new strategies to treat one of the most persistent and challenging treatment obsta
- 김갑성 기자
- 2025-12-05 16:00
Post-Disaster Support | Emergency Financial Assistance for…

HONG KONG, Dec. 5, 2025 -- The Level 5 fire at Wang Fuk House, Tai Po, on 26 November has left nearly 2,000 households homeless and plunged many families into hardship. Recovery and rebuilding after a disaster is a long journey that requires support from all sectors of society. To this end, the registered Hong Kong charity "Cancer Information.com.hk Charity Foundation" (Inland Revenue Department tax-exempt ref. no.: 91/15162), with generous funding from the Li Ka Shing Foundation, is launching an emergency drug subsidy programme specifically for cancer patients or survivors a
- 김갑성 기자
- 2025-12-05 14:03
TransThera Publishes Clinical Studies of Tinengotinib (TT…

NANJING, China and GAITHERSBURG, Md., Dec. 5, 2025 -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet Gastroenterology and Hepatology (Impact Factor: 38.6). Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, frequently driven by FGFR2 fusions-genomic alterations that are targetable by FGFR inhibitors such as pemigatinib and futibatinib. However, resistance to these agents commonly arises due to secondary FGFR2
- 김갑성 기자
- 2025-12-05 12:31
ALL CONEC Selected for Dream Venture Star 11, Prize Award and…

SEOUL, South Korea, Dec. 5, 2025 -- ALL CONEC has been selected for the Dream Venture Star (DVS) 11 "Oracle × Uclick Program Business Meetup" support initiative. The official event will take place on November 14 at the Daejeon Center for Creative Economy and Innovation, where ALL CONEC will receive a prize as a selected company and sign an official memorandum of understanding (MOU) related to the program. ALL CONEC develops digital prosthetic production solutions—including AI CAD, ERP, a 3D viewer, and IoT 3D printers—and provides a digital workflow platform that connec
- 김갑성 기자
- 2025-12-05 11:00
Agilent and Monash University Malaysia Mark 15-Year Partners…

[ 메디채널 김갑성 기자 ] Collaboration aimed at accelerating R&D in both small- and large-molecule analysis and building high-impact capabilities in fast-growing Asian markets KUALA LUMPUR, Malaysia, Dec. 5, 2025 -- Agilent Technologies Inc. (NYSE: A) announced the expansion of their strategic collaboration with Monash University in Malaysia to establish a state-of-the-art MUMPMP-Agilent BioDiscovery Hub aimed at accelerating regional biotechnology research and innovation. The new Memorandum of Understanding (MOU) was signed as part of the celebration of their 15-year strategic partnershi
- 김갑성 기자
- 2025-12-05 09:30
OTR Therapeutics Raises $100 Million in Series A Financing t…

SHANGHAI, Dec. 5, 2025 -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a $100 million Series A financing closed in June 2025. The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital. Founded in March 2025, OTR Therapeutics is establishing a novel, scalable, and capital-efficient model that synergizes internal R&D with strategic curation of high-potential external inn
- 김갑성 기자
- 2025-12-05 09:00
Innovent Biologics Announces Closing of Global Strategic P…

[ 메디채널 김갑성 기자 ] SAN FRANCISCO and SUZHOU, China, Dec. 5, 2025 -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option
- 김갑성 기자
- 2025-12-05 07:38
Renuka Iyer, MD, Named New Chief Medical Officer for National C…

[ 메디채널 김갑성 기자 ] Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and advance cancer care worldwide. PLYMOUTH MEETING, Pa., Dec. 4, 2025 -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers that publishes free evidence-based, expert consensus-driven guidelines for cancer prevention and care—today announced the hiring of Renuka Iyer, MD, as the new Chief Medical Officer (CMO) for the organization. Dr. Iyer has a long history of lead
- 김갑성 기자
- 2025-12-04 21:04
레누카 아이어 박사, NCCN 최고 의료 책임자로 선임

[ 메디채널 김갑성 기자 ] 로스웰파크 종합암센터의 저명한 종양학 전문의가 전 세계 암 치료 표준을 정립하고 개선하는 비영리 단체인 NCCN을 이끌 예정이다. 플리머스 미팅, 펜실베이니아주, 2025년 12월 4일 -- 미국 국립종합암센터네트워크(National Comprehensive Cancer Network®, NCCN®)가 오늘 레누카 아이어(Renuka Iyer) 박사를 신임 CMO로 선임했다고 발표했다. NCCN은 내로라하는 암 전문 병원들의 연합체로서 암 예방 및 치료에 관한 증거 기반의 무료 암 치료 가이드라인을 발간하고 있다. 아이어 박사는 오랫동안 종양학 분야의 선구자이자 혁신가로 활약해 왔다. 아이어 박사는 현재 NCCN 회원 기관인 [ 메디채널 김갑성 기자 ] 로스웰파크 종합암센터(Roswell Park Comprehensive Cancer Center)의 종양학 교수이자 위장관 종양학과장, 로스웰파크 의학부(Roswell Park's Department of Medicine) 교수 인사 담당 부처장, 그리고 로스웰파크 케어네트워크(Roswell Park Care Networ
- 김갑성 기자
- 2025-12-04 21:04
NovaBridge Announces Presentation of Ragistomig Expand…

[ 메디채널 김갑성 기자 ] Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profile The interim results, including immunological data on CD8+ cell proliferation and memory T-cell activation, are expected to be presented in a poster session at ESMO-IO on December 10, 2025
- 김갑성 기자
- 2025-12-04 20:34

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 19시 00분